Show/hide main menu

Research

Neurodevelopmental Disorders Clinical Trials Centre (NDD-CTC)

 DNA Pill_cropped1

Director - Professor Andre Strydom

Co-Directors - Professor Declan Murphy; Professor Grainne McAlonan
Clinical Trials Coordinator  - Maria Megalogeni

Our aim

We undertake clinical trials for the core symptoms and associated conditions of neurodevelopmental disorders in collaboration with industry partners, King’s clinical trials unit, KHP clinical trials office, the NIHR Maudsley Biomedical Research Centre and the NIHR / Wellcome Trust King's Clinical Research Facility. 

Our focus

The NDD-CTC undertakes fully powered clinical trials of  potential treatments  identified in our clinical trials pipeline based on shiftability and other experimental studies within the department, and includes treatments for individuals with Autism spectrum conditions, Down syndrome, and intellectual disabilities. 

 

Our Process

NDD-CTC Process
 biomarkers1

 

Step 1: 

Find biomarker of neurodevelopmental disorder or comorbid condition shared by a group of people 

 Shiftability2

 

Step 2:

Conduct 'shiftability study': target biomarker with dose of compound to test for response on biomarker

 Biological1

 

Step 3:

Does this make a biological difference?  NO - STOP  

 Pills_Fastfail1  

Step 4:

Yes - move forward to 'Fast Fail' trial  

 Brain_fastfail1


Step 5:  

Conduct 'Fast Fail' trial to test if we can maintain shift in the biomarker for ~weeks
NO - STOP 

 Pill Crop2


Step 6:

Yes - full clinical trial should be done in people we know should respond

Participants1

 

Step 7:
NDD-CTC conducts Phase II and III trials with ~hunderds of participant

 

Our current trials:

V1ADUCT  (NCT03504917; Sponsor – Hoffmann-La Roche)
This trial is to test  Balovaptan for social function in adults (18 years and older) with Autism – see here for details.

National coordinator (UK) – Professor Murphy; Local PI – Professor Andre Strydom; sub-investigators Dr Rejaul Islam and Dr Beata Kowalewska.  

 

STAR-AIMS (NCT03682978)
This trial will test if Arbaclofen will help to improve social function in children and young people (ages 5-17) with autism. This trial is part of the AIMS-2-TRIALS project.  

National Co-ordinator – Professor Andre Strydom; Investigators – Professor Tony Charman, Dr Eileen Daley, Dr Anya Kaushik.  

 

Find out more about our trials

If you would ike to find out more abouot our trials, please contact Maria Megalobeni: maria.megalogeni@kcl.ac.uk
 
Sitemap Site help Terms and conditions  Privacy policy  Accessibility  Modern slavery statement  Contact us

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454